Company intelligence / Profile preview
Singh Biotechnology
Tampa Bay, Florida, United Statessinghbiotechnology.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Singh Biotechnology is developing novel single domain antibodies that can cross cell membranes and the blood-brain barrier to target intracellular proteins. The FDA has granted orphan drug designation to its anti-STAT3 B VHH13 single domain antibody (SBT-100)[1].
- Therapeutic areas
- GastroenterologyOphthalmologyImmunologyDermatologyOncology
- Modalities
- Single domain antibodies (sdAbs)Monoclonal antibodiesBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Singh Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Singh Biotechnology.